Twitter

Analyst Group comments on Chordate’s Q2 report: “subgroup results could be a real value driver”

Analyst Group writes in a comment on Chordate Medical’s Q2 report that the company’s chosen strategy in the UK, which is now also being implemented in Germany and Israel, could result in a faster expansion.

“As we have previously written, we believe that Chordate’s chosen strategy in the UK could result in a faster expansion in the market, which would thus also be reflected in Chordate’s sales figures. We therefore view positively that the company has chosen to apply this strategy in Israel and Germany as well.”

Analyst Group also comments on the subgroup results that will be presented at the Migraine Trust International Symposium 2022 in London on September 8th.

“The subgroup results that will be presented next week could be a real value driver in Chordate’s share, given that the results are good. This as the results would constitute direct support for the company’s marketing of, and sales targets for, the K.O.S treatment for patients with chronic migraine. This is therefore something an investor should monitor.”

Read the full analyst commentary (in Swedish)

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter